BRIACELL THERAPEUTICS CORP. Net Income (Loss) Available to Common Stockholders, Diluted
BRIACELL THERAPEUTICS CORP. (BCTX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$5.80 million for the 3-month period ending 2024-10-31, per its 10-Q filed 2024-12-16.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2024-12-16
- BRIACELL THERAPEUTICS CORP. net income (loss) available to common stockholders, diluted for the quarter ending 2024-10-31 was -$5.80M.
- BRIACELL THERAPEUTICS CORP. net income (loss) available to common stockholders, diluted for the quarter ending 2023-10-31 was -$8.28M.
- BRIACELL THERAPEUTICS CORP. net income (loss) available to common stockholders, diluted for the quarter ending 2022-10-31 was -$1.11M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month |
|---|---|
| 2024-10-31 | -$5.80M 10-Q · filed 2024-12-16 |
| 2023-10-31 | -$8.28M 10-Q · filed 2024-12-16 |
| 2022-10-31 | -$1.11M 10-Q · filed 2023-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |